LivaNova upgraded to Outperform from Peer Perform at Wolfe Research

Wolfe Research upgraded LivaNova (LIVN) to Outperform from Peer Perform with a $60 price target The firm says that since its downgrade, LivaNova’s valuation has compressed, its Italian legal overhang has lifted at a total liability a little less than “worst case,” and it made a commitment to expand oxygenator capacity into next year, which could produce “step change” in its ability to supply 2026. In addition, management recently sounded “cautiously more-optimistic-than-expected” on the pathway with Medicare for depression, the analyst tells investors in a research note.